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Abstract  
 
Background Studies examining the risk of herpes zoster (HZ) associated with 
immunosuppressants, such as biologics, non-biological disease modifying agents 
(nbDMARDs) or corticosteroids, have generated conflicting results.   
Methods  We conducted a systematic literature search from Jan 1946 to Feb 2016.  
Search terms related to HZ, rheumatoid arthritis, psoriasis, psoriatic arthritis, 
systemic lupus erythematous or inflammatory bowel disease, biologics, nbDMARDS 
and corticosteroids were used. We included randomized controlled trials (RCTs) 
and observational studies reporting associations between immunosuppressants and 
HZ outcomes in adults. For RCTs, we used the Mantel-Haenszel fixed-effects model 
to estimate pooled odds ratios (OR) and 95% confidence intervals (CI) for HZ risk. 
For observational studies, adjusted ORs were pooled separately using random-
effects inverse variance models.   
Findings Data were pooled from 40 eligible RCTs (20,136 patients) and 19 
observational studies (810,939 patients). Biologics were associated with a greater 
risk of HZ than control (RCTs: OR 1.71, 95% CI 1.11-2.64; Observational studies: OR 
OR 1.58, 95% CI 1.39-1.81). In RCTs, the OR of non-TNF blockers was 2.19 (95% CI 
1.20-4.02), but that of TNF blockers was not significantly different from control. 
Increased risks of HZ with nbDMARDs (OR 1.21, 95% CI 1.15-1.28) and 
corticosteroids (OR 1.73, 95% CI 1.57-1.89) were observed in observational studies, 
but few RCTs examined these comparisons.   
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Conclusions Immunocompromized patients receiving biologics were associated 
with an increased risk of HZ.  The risk is also increased with corticosteroids and 
nbDMARDs. These findings raise the issue of prophylaxis with zoster vaccine in 
patients initiating immunosuppressive therapy for autoimmune diseases.  
 
Keywords: Herpes zoster, meta-analysis, DMARDS, biologics, autoimmune diseases, 
rheumatoid arthritis, immunocompromised 
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Introduction  
 
Infection with varicella zoster virus, usually during childhood, leads to the virus 
seeding sensory ganglia and remaining dormant.1  Reactivation of the virus later in 
life leads to herpes zoster (HZ) or shingles infection,1 which is characterized by a 
unilateral vesicular and painful rash, usually in a single dermatome.2  HZ causes 
much morbidity including pain, depression, and long-term disability in the form of 
postherpetic neuralgia (PHN), pain that continues after the rash has subsided.2,3   
More than ninety percent of the population has serologic evidence of varicella 
infection and approximately 1 in 3 persons will develop HZ during their lifetime, 
leading to approximately 1 million HZ cases per year in the United States.1,4   
However, the majority of treatment for HZ and PHN takes place on an outpatient 
basis with reported rates of HZ-related hospitalization ranging widely from 2 to 25 
per 100,000 person-years.5  The medical cost of treating HZ in the United States has 
been estimated to be around $1.1 billion US dollars per annum.6    
 
Rates of HZ infection in the general population are around 3 to 5 per 1000 person 
years, and interestingly these rates are increasing over time.4,5  The risk of HZ seems 
to increase with decreasing cellular immunity, which is responsible for holding the 
varicella virus in check.7 Thus, the most important risk factors for developing HZ are 
age and decreasing immune status.1,5  For example, studies have shown that rates of 
HZ infection in those 60 years of age and over is 6-8 per 1000 person years, and rise 
to 8-12 per 1000 person years in persons 80 years of age.1,5  HZ risk is also higher in 
individuals who are immunocompromised due to autoimmune diseases, solid organ 
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or stem cell transplants, HIV and/or immunosuppressive medications that impair  T-
cell immunity.8  These medications include corticosteroids, biologics, such as TNF-
alpha blockers, or non-biologic disease modifying anti-rheumatic drugs 
(nbDMARDs), that is, conventional synthetic disease modifying anti-rheumatic 
drugs (csDMARDs), such as methotrexate and targeted synthetic disease modifying 
anti-rheumatic drugs (tsDMARDs) as tofacitinib.8  Not only are elderly and 
immunocompromised individuals at higher risk for HZ, but they are also more likely 
to develop HZ-related complications. As such, studies have found the medical costs 
of treating HZ for immunocompromised patients to be nearly twice as high as other 
HZ patients, due to the higher rates of PHN and other complications in this group.5,6  
 
There are multiple studies reporting the risk of HZ associated with individual 
immunosuppressants in patients with autoimmune diseases such as rheumatoid 
arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematous (SLE) and 
inflammatory bowel disease (IBD). However, the results are conflicting and 
statistical significance is often not detected due to the low incidence of HZ. We 
therefore conducted a systematic review and meta-analysis of published studies to 
assess the association of biologics, nbDMARDs, corticosteroids or combinations and 
risk of HZ in adults with autoimmune diseases. 
 
Methods 
This systematic review and meta-analysis was reported according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)9 statement 
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for RCTs and guidelines for the reporting of observational studies and adverse 
events. 10,11  A pre-specified study protocol was developed prior to the literature 
review and followed, but was not registered. 
 
Literature Search  
We conducted a systematic literature search using MEDLINE, EMBASE, Google, 
Google Scholar, Cochrane, CAB Direct, CINAHL, Web of Knowledge, and PubMed for 
articles reporting on herpes infection in immunocompromised patients published 
between January 1946 and February 2016. Search terms, as both keywords and 
subject headings, included (Immunosuppress*, antirheumatic*, methotrexate, 
azathioprine, 6-mercaptopurine, cyclophosphamide, cyclosporine, prednisone, 
corticosteroids, steroids, leflunomide, mycophenolate, tacrolimus, sirolimus, infliximab, 
adalimumab, etanercept, abatacept, rituximab, golimumab, certolizumab, tocilizumab, 
apremilast, ustekinumab, vedolizumab, biologics, mono-clonal antibodies, tumour 
necrosis factor (TNF) antibody, TNF, disease modifying agent, disease modifying 
antirheumatic drug (DMARD), DMARD, anakinra, natalizumab, tofacitinib, 
belimumab) AND (SLE, IBD, Crohn’s disease, ulcerative colitis, RA, ankylosing 
spondylitis [AS], psoria*) AND (HZ, herpes virus, shingles). We also conducted a 
manual search by reviewing the reference lists of included studies. The literature 
search was performed by two authors (EL/VK). Uncertainty and revisions were 
discussed with another author (FM). 
 
Inclusion and Exclusion Criteria  
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We included studies if they compared the incidence of HZ between biologics, 
nbDMARDs, corticosteroids or placebo in adults with RA, psoriasis, psoriatic 
arthritis, SLE or IBD. We only included the biologicals that have been approved by 
the FDA and/or EMA. Only randomized controlled trials (RCTs) and observational 
studies (OBS), consisting of cohort studies and case-control studies, were eligible.  
We excluded SLE and non-SLE RCTs with fewer than 15 and 50 patients in each arm, 
respectively, because they were unlikely to be able to detect sufficient HZ events.12   
Due to the lack of randomisation in observational studies, eligible studies were 
those providing adjusted or propensity score matched associations.  We excluded 
non-English, non-human, non-adult (i.e., juvenile disease), and unpublished studies. 
Finally, although individuals with HIV, solid organ transplant and cancer may also 
receive treatment with biologicals, nbDMARDS and/or corticosteroids, we excluded 
these individuals as the mechanisms of the immunosuppression is distinct in each of 
these diseases and thus it is very likely that the background risk of HZ is very 
different in each of these diseases.  
 
Data Extraction, Study Verification and Quality Assessment  
Data was extracted independently by two authors (EL/VK) using a standardised 
abstraction form. Discrepancies were resolved through discussion with two other 
authors (FM/KR). Data extracted from the studies included the author, date of the 
study, baseline characteristics of patients (underlying autoimmune disease, age, 
sex), total number of subjects, study duration, treatment, number of patients in each 
Herpes zoster in the immunocompromised….. 8 
medication group, duration of treatment, person-years, HZ definition, and incidence 
of HZ within the different medication groups.  
 
For RCTs, where possible, we included all adverse events reporting of HZ. If not 
recorded as such, we examined serious adverse events (SAE) of HZ, which were 
generally defined as HZ that is either life-threatening, causing hospitalization, or 
significant disability or incapacity. For the observational studies we included 
outcome definitions of HZ from either diagnostic records and/or adjunctive use of 
antiviral medications, patient or physician report. Although the primary data source 
was published data, for the RCT data, we searched the U.S. National Institutes of 
Health trial registry and results database (https://clinicaltrials.gov) and contacted 
all principal investigators to verify the HZ definition used, whether SAE or not, and 
the reported numbers.   We also contacted authors of observational studies if any 
clarification was needed. 
 
Two authors (EL/VK) independently conducted the quality assessment of the 
studies using the Cochrane Risk of Bias tool13 and the Newcastle-Ottawa quality 
assessment scale14 for RCTs and cohort/case-control studies, respectively. Points 
were awarded to observational studies for comparability if they controlled or 
adjusted for age and concomitant medications as both are considered important risk 
factors for HZ.1,8 Discrepancies were resolved through discussion with another 
author (FM/KR). 
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Statistical Analysis 
As HZ is a rare event, we used the Mantel-Haenszel fixed-effects model to calculate 
pooled odds-ratios and 95% confidence intervals (CI) for the risk of HZ associated 
with various immunosuppressants from the RCT data.15  Due to imbalances in 
patient numbers across some study arms, we applied a continuity correction that 
was inversely proportional to the relative size of the opposite arm of the study.16      
For observational studies, adjusted ORs were pooled separately using the inverse 
variance method.  Random effects models were used due to expected heterogeneity. 
  
Primary analyses compared the risk of HZ of biologics (categorised by anti-TNF and 
non-TNF), nbDMARDs, and corticosteroids to control/placebo. For the RCTs we 
either compared biologics to placebo or biologic + control therapy to control 
therapy.  Secondary analyses compared the risk of HZ in biologics to the nbDMARDS 
and in combination treatments (biologics and nbDMARDS) compared to 
control/placebo. 
 
We measured heterogeneity across studies using the I2 statistic, with higher values 
reflecting increasing heterogeneity.16  Sources of heterogeneity were assessed by 
subgroup analysis and by meta-regression.  Specifically, subgroups were examined 
by disease, mean age, gender ratio, and RCT outcomes categorized both according to 
general AE/SAE and high risk of bias or not.  We assessed publication bias by 
examining funnel plots and performing the Egger test for asymmetry.17 Pooling RCT 
data with many zero events can lead to mathematical instability, and although the 
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Mantel-Haeszel fixed effect method has been shown to perform well for this 
situation,15 as a sensitivity analysis we also estimated the pooled RCT estimates 
using a fixed-effects Peto method and random-effects Poisson regression which also 
allow for baseline study variability and any between study heterogeneity.18,19 Stata 
version 12.1 (StataCorp, College Station, TX) was used for analysis. Statistical tests 
were two sided with p<0.05 defining statistical significance. 
 
Results 
 
Search Results and Trial Characteristics 
The literature search and the manual search of reference lists identified 4225 
studies (Figure 1).  Of these, the majority were excluded after reviewing the title 
and/or abstract. Two hundred and eighty one studies were included for a full article 
review and 57 studies were included after detailed assessment, corresponding to 40 
RCTs (2 studies reported results of 2 RCTs in one paper),20–57 16 cohort studies,58–72 
and 3 case-control studies.73–75  Reasons for exclusion were mainly irrelevance, 
study design, duplication and lack of quantitative data about the incidence of HZ 
associated with individual medication or medication class.   
 
The baseline characteristics of the patients included for analysis are summarized in 
Tables 1 and 2.  In total 20,136 patients were included in the RCTs and 810,939 in 
the observational studies. The mean age of patients ranged from 25 to 75 years and 
the percentage of women ranged from 9 to 87%. Study follow-up duration ranged 
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from 6-104 weeks in the RCTs and 37-600 weeks in the observational studies. Most 
studies focused on RA patients (25 of 40 RCTs and 14 of 19 observational) while a 
smaller number evaluated other autoimmune diseases. A wide variety of biologic 
agents, nbDMARDs, corticosteroids and various combinations of these agents were 
evaluated.  
 
Included Studies and the Risk of Bias  
Assessment of study validity revealed a potential risk of bias amongst some RCT 
studies (eTable 1), with 21 of 40 being graded as having a ‘high’ risk of bias in any 
domain and only 6 RCTs rated with a low risk of bias across all domains. “Unclear” 
was graded for most studies due to a lack of description of the details of sequence 
generation and allocation concealment. While many of the studies claimed a 
“double-blind” design, few of them explicitly described the parties that were blinded. 
The risk for incomplete outcome data was graded as “high” for 18 of 40 RCTs as 
their drop-out rates exceeded 20%.  In contrast, the included observational studies 
were found at low risk of bias with scores ranging from 7/9 to 9/9, as a 
consequence of our inclusion criteria (eTable 2 and 3).  
 
Risk of Herpes Zoster with Biologics  
Twenty-eight RCTs (n=12,272) and 6 observational studies (n=132,647) reported 
the risk of HZ associated with biologics compared to control or no therapy (Figure 
2). Biologics were associated with an increased risk of HZ than control in the RCT 
data (OR 1.71, 95% CI 1.11-2.64; I2=0%) (Figure 2a) and in the observational 
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studies (OR 1.58, 95% CI 1.39-1.81; I2=0%) (Figure 2b). Stratified analysis of the 
RCT data according to TNF-alpha inhibitors, demonstrated a greater risk of HZ for 
the non-TNF-alpha inhibitors compared to placebo (OR 2.19, 95% CI 1.20-4.02; 
I2=0%) and no statistically significant difference for the TNF-alpha inhibitors (OR 
1.28, 95% CI 0.69-2.40; I2=0%) (Figure 2a).  
 
Risk of Herpes Zoster with Non-Biologic DMARDS 
The pooled odds ratio for HZ with nbDMARDS compared to control across 16 RCTs 
was 1.61 (95% CI: 0.84-3.10, I2=0%) (Figure 3a) and across 6 observational studies 
was 1.21 (95% CI: 1.15-1.28, I2=15%)(Figure 3b). Only the 10 RCTs studying 
tofacitinib examined the impact of nbDMARD dose on HZ risk. The pooled ORs (95% 
CI) for 1-3mg, 5mg, 10mg, and 15-30mg BID of tofacitinib were 0.34 (95% CI: 0.05-
2.27), 2.10 (95% CI: 0.83-5.34), 3.01 (95% CI: 1.15-7.87), and 0.63 (95% CI: 0.16-
2.52), respectively (eFigure 1). However, this analysis is limited by few RCTs 
examining tofacitinib at 1-3 or 15-30mg BID.  
 
Risk of Herpes Zoster with Corticosteroids 
No RCTs and 15 observational studies evaluated corticosteroids. The risk of HZ 
associated with corticosteroid use was increased significantly (OR 1.73, 95% CI: 
1.57-1.89), although there was considerable heterogeneity (I2=76%) (Figure 4). 
Study characteristics did not explain the heterogeneity. Only 6 studies reported 
associations for HZ risk by corticosteroid dose. Two studies found no difference in 
HZ risk across dose, whereas 4 studies demonstrated increasing HZ risk with 
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greater dose, in particular with greater than 10mg per day (eTable 4). Since the risk 
of reporting bias cannot be ruled out, further analysis of corticosteroid dose was not 
performed.  
 
Secondary Analyses  
Pooled data from 7 RCTs (OR 0.82, 95% CI: 0.40-1.67, I2=0%) and 5 observational 
studies (OR 1.06, 95% CI: 0.69-1.61, I2=71%) failed to show a significantly greater 
HZ risk with biologics compared to nbDMARDs (eFigure 2).  Combination treatment 
of biologics and nbDMARD was compared to no use in 3 observational studies, and 
was associated with a greater risk of HZ (OR 2.25, 95% CI: 1.32-3.66, I2=74%), 
although there was considerable heterogeneity (eFigure 3). 
 
None of the findings varied significantly by age or sex; nor by high risk of bias or 
reporting of AE vs SAE for the RCT data. When evaluating the risk by disease state, 
there was the suggestion of reduced risks in rheumatoid arthritis patients compared 
to the other diseases in the RCTs, but not in the observational studies (eTable 5). 
There was also no evidence of publication bias (eFigure 4 displays the funnel plot 
for the RCT data comparing biologics to control therapy). Pooled effect sizes for the 
RCT data were generally similar when we used either the fixed-effects Peto method 
or random-effects Poisson regression (eTable 6).  
 
 
Discussion 
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This is the first review to systematically examine the risks of HZ associated with 
immunosuppressants across various autoimmune disease states whilst including 
evidence from RCTs.  Our meta-analysis indicates an elevated risk of HZ in 
immunosuppressed patients treated with biologics in both RCT and observational 
studies. Interestingly, elevated risk of HZ was observed with non-TNF-alpha 
blocking agents but not TNF-alpha inhibitors. There was also evidence that 
treatment with corticosteroids or nbDMARDs increases the risk of HZ.  
 
Two meta-analyses have evaluated HZ risk with immunosuppressive medications in 
RA patients specifically.76,77  Kourbeti et al examined opportunistic infections due to 
biologics from 70 RCTs (N=21,916).76 As a secondary analysis including 11 RCTs, 
they also examined varicella-zoster infection, and found similar findings to our 
study, albeit not reaching statistical significance (OR 1.51, 95%CI 0.71-3.22).   Che et 
al compared TNF-alpha blockers (N=73,510) with nbDMARDs (N=89,567) from 
crude numbers obtained from observational studies and found an elevated risk of 
HZ (OR 1.61, 95%CI 1.16-2.23).77 This association is probably greater than our 
pooled estimates as confounding factors such as age and disease severity were not 
accounted for.  Numerous meta-analyses have evaluated the general risk of serious 
infections or opportunistic infections, defined as development of a mycobacterial, 
fungal, or viral infection, during treatment with biologics and/or nbDMARDs. These 
studies have shown a clear risk of granulomatous infections, such as tuberculosis 
with biologics, but not necessarily for viral infections, although this may be related 
to lack of standardized reporting in RCTs.8,76,78,79  There were insufficient RCT data 
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to enable us to examine HZ risk according to specific biological agents, but we did 
stratify our analysis according to the type of biologic and found evidence of a 
greater risk of HZ with non-TNF biologics. However, this finding needs to be 
corroborated by other investigators. Contrary to our findings, in their secondary 
analysis, Kourbeti and colleagues found anti-TNF blocking agents, but not non-TNF-
alpha blocking agents, to be associated with a significant risk of opportunistic 
infections (OR 2.10; 95%CI 1.27-3.45).76  The authors suggested this may be due to 
heightened awareness of infectious complications in recent trials or that newer non-
TNF-alpha blocking agents have a lower risk for opportunistic infections.  
 
The conflicting data seen in the various reviews is likely related to whether the 
endpoint is risk of opportunistic infections or HZ specifically, the disease stage of 
the patients, given that some studies have shown a higher risk earlier on in their 
treatment course, as well as which particular immunosuppressive agents are being 
assessed.78  Biologics, nbDMARDs and corticosteroids impair B-cell and T-cell 
immunity through different mechanisms; and therefore one can expect different 
degrees of immunosuppression and different effects depending on whether the 
pathogen is bacterial, fungal or viral. Furthermore, all biologics do not have the 
same mechanism of action, for example, those considered monoclonal antibodies, 
such as infliximab, golimumab, adalimumab and certolizumab bind to both free 
floating and membrane bound TNF-alpha receptors;80–82  etanercept also inhibits 
TNF-alpha but is not a monoclonal antibody and binds to free TNF-alpha receptors 
only. 81  Additionally, the monoclonal antibodies can lyse other cells involved in the 
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inflammatory process, whereas the receptor fusion protein, etanercept, lacks this 
capability. 81  Non-TNF alpha blocking agents are more of a mixed bag, exploiting 
different targets, like antigen presenting cells (abatacept),83 pro-inflammatory 
cytokines, B cell depleting monoclonal antibodies binding CD20 (rituximab),84 and 
therefore may have very different risk for the various microbes compared to the 
monoclonal TNF-alpha inhibitors.   These differential mechanisms may be 
contributing to the differential risk with respect to serious infections and further 
studies are needed to elucidate the specific infectious risk associated with specific 
agents.  
 
Our meta-analysis found an increased HZ risk of around 21-61% with nbDMARD 
treatment, but this only reached statistical significance in the pooled observational 
studies. This may be due to the RCTs being under-powered to detect differences in 
rare adverse events like HZ.79  The types of nbDMARD used in the trials and clinical 
practice vary considerably and our meta-analysis studies included 8 different 
nbDMARDs, as such we were not able to stratify results by drug, other than 
tofacitinib which had enough RCTs for us to pool the results.  We found that much of 
the increased risk associated with the nbDMARDs was related to the newer JAK 
inhibitor, tofacitinib, rather than the conventional DMARDs.  Increased HZ with 
tofacitinib was also seen in Winthrop et al’s meta-analysis, which evaluated data 
from Phase II and III studies and showed a crude IR of 4.4/100 person-years (95% 
CI: 3.8-4.9), almost 3 times the rate for TNF-alpha inhibitors; the risk occurred early 
in the treatment course rather than later.85   When evaluating the data according to 
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the tofacitinib dose, we generally observed higher doses posing an increased risk of 
HZ.  Our literature search was completed in February 2016 and therefore we did not 
include two further studies published recently evaluating the JAK inhibitors 
baricitinib86 and ruxolitinib87, both appear to cause an increased risk of zoster 
infection.  
 
Our meta-analysis of observational studies also showed an increased HZ risk with 
corticosteroid use. Corticosteroids impact almost all immune cells through 
transcriptional regulation of gene targets and inhibition of cellular proliferative 
responses by impairing phagocyte function and suppressing cell-mediated 
immunity, thereby plausibly increasing the risk of infection.88 A meta-analysis of 21 
RCTs and 42 observational studies showed that steroid therapy was not associated 
with a risk of infection (RR 0.97, 95% CI 0.69-1.36) when data was pooled from the 
RCTs, but the observational studies generated a RR of 1.67 (95% CI 1.49-1.87), 
although significant heterogeneity was present.89  The authors concluded that the 
small number of events in the RCTs likely precluded seeing a clinically important 
increased or decreased risk. Our results also showed considerable heterogeneity 
and should be interpreted with caution. The heterogeneity could be due to a 
combination of differences in study design (e.g. the inclusion of new users vs 
prevalent users), the ability to account for disease severity, or definitions of the 
control group and of HZ; however we were not able to identify any consistent 
predictors.   Most included studies did not examine the association between 
corticosteroid use and HZ as a primary hypothesis and this could have contributed 
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to the varying results.  The dose-related increases in zoster risk reported by 
included studies is in keeping with guideline development reviews which have 
identified that higher doses and longer treatment duration confer a greater risk of 
serious infection.90,91   
 
Our study is not without limitations. We were limited by the reporting of HZ. In the 
RCTs, HZ was either reported as a SAE or an AE and rather than being reported as a 
separate entity, was often reported under other categories such as skin infection. 
We may have missed smaller studies that did not report their HZ events and we 
excluded unpublished and non-English studies, however we saw no evidence of 
publication bias. The studies that reported on HZ events were usually of better 
quality as they were larger and they had structured protocols to capture rare 
adverse events. We verified the number of HZ events in 83% of RCTs. Restricting 
our analysis of biologics to those verified did not affect our findings.  
 
The minority of RCTs with substantial attrition rates are a concern. Generally they 
experienced greater numbers discontinuing the placebo arms due to lack of efficacy, 
which could have resulted in lower HZ events in the placebo arm. Conversely, 
studies have noted discontinuation of corticosteroid use amongst patients in 
biologics arms,20,41,45 suggesting reduced HZ risk in those arms. Hence we do not 
believe HZ was consistently differentially under- or over-reported in treatment 
arms. Additionally, our findings were consistent when restricted to the studies 
without a high risk of bias. Our pooled estimates from the RCT data were potentially 
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mathematical unstable as they were based on few events.8 However, we used 
appropriate methods for pooling rare event data, and our estimates were very 
similar when other statistical approaches were applied.  Unfortunately we were 
unable to examine the effect of biologic dose on HZ risk as the majority of RCTs used 
recommended doses. We found no significant differences in HZ risk when 
comparing those using recommended to those using the higher end of 
recommended doses for biologics (results not shown).  However, both the 
nbDMARD, tofacitinib and the corticosteroids showed evidence of dose-response 
relationships.  
 
Our RCT meta-analysis is strengthened by the consistent parallel evidence observed 
from pooled observational studies that were also of high quality due to their 
adjustment for relevant confounders. The observational studies all adjusted for age, 
sex, concomitant medications, and the majority adjusted for at least a proxy for 
disease severity, and as such there can be considered to be limited remaining 
residual confounding.  
 
Other than prompt diagnosis and initiation of antiviral therapy, prophylaxis with 
vaccination is an effective strategy against zoster infection. Zostavax® has been 
demonstrated in largely healthy elderly patients of 60 years and above to decrease 
the risk of HZ by 51% in the 3 years post vaccination, with rates of SAE similar with 
placebo group;92 a new adjuvanted, non-live varicella-zoster vaccine was recently 
tested in a phase 3 clinical trial in adults 50 years or above and found to have an 
overall efficacy of 97%.93  Unfortunately, zoster vaccine is a live vaccine and is 
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therefore not recommended to be administered to immunocompromised 
individuals, although a US study in which immunocompromised individuals who 
inadvertently received HZ vaccine did not have increased risk of HZ infection 
compared to controls.71 Given the numerous findings on the risk of HZ with biologics, 
and the trend seen in our study with respect to nbDMARDS and corticosteroids, we 
recommend following the ACIP issued guidance and offering the vaccine to patients 
before starting therapy.94,95  To better determine its safety profile, further efficacy 
trials of the non-live herpes zoster vaccine in patients with autoimmune disorders 
are also needed.  
 
Conclusions 
We demonstrated an increased risk of HZ in immunocompromized patients 
receiving biologics, especially non-TNF-alpha blockers. Increased HZ risk from 
corticosteroid and nbDMARD use was also observed in observational studies. The 
use of biologics and DMARDS is now commonplace, not only in rheumatoid arthritis 
patients but a host of other autoimmune diseases. Our findings raise the issue of 
appropriate medical history and screening of patients before treatment prior to 
initiating immunosuppressants. Finally, not all biological agents are equal with 
respect to their potential for opportunistic infections and post-marketing 
surveillance of these newer agents with different mechanisms of action than the 
traditional TNF-alpha inhibitors is vital.  
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Key Messages 
Herpes zoster is increased in patients receiving biologics, especially non-TNF-alpha 
blockers, although all biologics do not pose the same risk.  Patients are also at risk 
for zoster infection if placed on corticosteroids or non-biologic DMARDS.  
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